CCT303-406

· Shanghai PerHum Therapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CCT303-406, covering 2024-10-28 to 2024-10-28. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors [Phase 1]